On August 13, 2026, Danish-Swedish initiative Next Phase Femtech launched with €1.6 million from the EU's Interreg Öresund-Kattegat-Skagerrak program, aimed at moving women's health solutions from prototype to market. The three-year initiative is led by the Research Unit at Zealand University and was reported by Femtech Insider.

Why It Matters

The femtech funding conversation is dominated by venture rounds, but the sector's actual bottleneck is proof — specifically, evidence generated inside real health systems that payers and employers will accept. Non-dilutive public money aimed squarely at implementation testing addresses a gap that VC structurally will not fund, because the payoff is a validated care pathway rather than a growth curve. The timing sharpens the point. This week also brought Midi Health's pivot beyond menopause into broader women's health, and last week brought the shutdown of perimenopause platform Play Health, whose CEO said the category "continues to be a 'nice to have'" that neither cash pay nor insurance would reimburse. Next Phase Femtech is attacking exactly that failure mode from the opposite direction: instead of building a consumer product and hunting for reimbursement afterward, it embeds the products inside regional health institutions and municipal employers from the start, and treats policy influence as a deliverable. It also fits a broader European pattern of public capital doing the de-risking that private capital won't — alongside Innovate UK's Women in Innovation grants to Papcup and Peripear, and Germany's SPRIND backing of hormone-sensing work. For US operators, the strategic read is that Nordic and UK health systems are becoming the cheapest place in the world to generate the clinical and workplace evidence that later unlocks American payer conversations.

Its opening cohort is deliberately narrow: three market-ready menopause solutions — workplace advocacy organization Hormoner på Arbejde, digital health platform MeWe&You Health, and AI-assisted symptom management app Minimal. Rather than an accelerator demo-day model, the program will test those solutions with healthcare professionals across institutions in Region Zealand, Region Skåne and Tomelilla Municipality, with the explicit goal of establishing future workplace solutions and policies.

The test population is the sharpest part of the design. "Women in healthcare are holding up the system while often managing their own menopause symptoms with no support and no data to back them up," said Minimal founder Jacqueline Nuwame. "Next Phase Femtech lets us test real tools with the people who need them most, and turn what we learn into meaningful data, the foundation of a body of knowledge on menopause that's been missing for far too long." Beyond the initial three, the program plans to recruit 30 companies across women's health, offering market insight, business development, implementation support and networking.

Sources

Update — 2026-08-19

Initial entry — story first created.